Pharmacokinetics and safety of adjunctive topiramate in infants (1-24 months) with refractory partial-onset seizures: A randomized, multicenter, open-label phase 1 study

Epilepsia

Volumn 54, Issue 1, 2013, Pages 156-164

  Manitpisitkul, Prasarn ^a   Shalayda, Kevin ^a   Todd, Mike ^a   Wang, Shean S ^a   Ness, Seth ^a   Ford, Lisa ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antiepileptic drug; Area under curve; Concentration time; Drug interaction; Enzyme induction; Tolerability

Indexed keywords

CREATININE; TOPIRAMATE;

ADJUVANT THERAPY; AGE; ANOREXIA; ANTICONVULSANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; BRONCHITIS; CONTROLLED STUDY; COUGHING; CREATININE CLEARANCE; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOCAL EPILEPSY; HEAD CIRCUMFERENCE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OTITIS MEDIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SEIZURE; SIDE EFFECT; SOMNOLENCE; STEADY STATE; TONIC SEIZURE; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; VOMITING;

ANTICONVULSANTS; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; FRUCTOSE; HUMANS; INFANT; INFANT, NEWBORN; MALE;

EID: 84872070740     PISSN: 00139580     EISSN: 15281167     Source Type: Journal    
DOI: 10.1111/epi.12019     Document Type: Article

References (27)

1. Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN,. (2006) Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45: 1077-1097.
2. Benedetti MS, Whomsley R, Baltes EL,. (2005) Differences in absorption, distribution, metabolism and excretion of xenobiotics between the paediatric and adult populations. Expert Opin Drug Metab Toxicol 1: 447-471.
3. Britzi M, Soback S, Isoherranen N, Levy R'H, Perucca E, Doose DR, Maryanoff BE, Bialer M,. (2003) Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit 25: 314-322.
4. Dahlin MG, Ohman IK,. (2004) Age and antiepileptic drugs influence topiramate plasma levels in children. Pediatr Neurol 31: 248-253.
5. Ferrari AR, Guerrini R, Gatti G, Alessandri MG, Bonanni P, Perucca E,. (2003) Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 25: 700-708.
6. Glauser TA, Miles MV, Tang P, Clark P, McGee K, Doose DR,. (1999) Topiramate pharmacokinetics in infants. Epilepsia 40: 788-791.
7. Janssen Pharmaceuticals. (2011) Topamax prescribing information. Janssen Pharmaceuticals, Titusville, NJ.
8. Kugler SL, Sachdeo RC,. (1998) Topiramate efficacy in infancy. Pediatr Neurol 19: 320-322.
9. Laughon MM, Benjamin DK Jr, Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barrett J, Smith PB, Cohen-Wolkowiez M,. (2011) Innovative clinical trial design for pediatric therapeutics. Expert Rev Clin Pharmacol 4: 643-652.
10. Longin E, Teich M, Koelfen W, Konig S,. (2002) Topiramate enhances the risk of valproate-associated side effects in three children. Epilepsia 43: 451-454.
11. May TW, Rambeck B, Jurgens U,. (2002) Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Ther Drug Monit 24: 366-374.
12. Mikaeloff Y, Rey E, Soufflet C, d'Athis P, Echenne B, Vallee L, Bouhours P, Grinspan A, Dulac O, Pons G, Chiron C,. (2004) Topiramate pharmacokinetics in children with epilepsy aged from 6 months to 4 years. Epilepsia 45: 1448-1452.
13. Novotny E, Renfroe B, Yardi N, Nordli D, Ness S, Wang S, Weber T, Kurland CL, Yuen E, Eerdekens M, Venkatraman L, Nye JS, Ford L,. (2010) Randomized trial of adjunctive topiramate therapy in infants with refractory partial seizures. Neurology 74: 714-720.
14. Philippi H, Boor R, Reitter B,. (2002) Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 43: 744-747.
15. Puri V, Ness S, Sattaluri SJ, Wang S, Todd M, Yuen E, Eerdekens M, Nye JS, Manitpisitkul P, Shalayda K, Ford L,. (2011) Long-term open-label study of adjunctive topiramate in infants with refractory partial-onset seizures. J Child Neurol 26: 1271-1283.
16. Reed MD,. (1999) Optimal sampling theory: an overview of its application to pharmacokinetic studies in infants and children. Pediatrics 104: 627-632.
17. Ritter F, Glauser TA, Elterman RD, Wyllie E,. (2000) Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group. Epilepsia 41 (Suppl. 1): S82-S85.
18. Rosenfeld WE, Liao S, Kramer LD, Anderson G, Palmer M, Levy RH, Nayak RK,. (1997) Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 38: 324-333.
19. Rosenfeld WE, Doose DR, Walker SA, Baldassarre JS, Reife RA,. (1999) A study of topiramate pharmacokinetics and tolerability in children with epilepsy. Pediatr Neurol 20: 339-344.
20. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR,. (1996) Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 37: 774-780.
21. Sachdeo RC, Sachdeo SK, Levy RH, Streeter AJ, Bishop FE, Kunze KL, Mather GG, Roskos LK, Shen DD, Thummel KE, Trager WF, Curtin CR, Doose DR, Gisclon LG, Bialer M,. (2002) Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 43: 691-696.
22. Schwartz GJ, Gauthier B,. (1985) A simple estimate of glomerular filtration rate in adolescent boys. J Pediatr 106: 522-526.
23. Shank RP, Maryanoff BE,. (2008) Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 14: 120-142.
24. Ten Eick AP, Reed MD,. (2000) Clinical pharmacology research in the pediatric patient: the challenge continues. Prog Pediatr Cardiol 12: 29-35.
25. Valencia I, Fons C, Kothare SV, Khurana DS, Yum S, Hardison HH, Legido A,. (2005) Efficacy and tolerability of topiramate in children younger than 2 years old. J Child Neurol 20: 667-669.
26. Veggiotti P, Longaretti F, Signorini S, Cardinali S, Lanzi G,. (2004) Topiramate efficacy in an infant with partial seizures refractory to conventional antiepileptic drugs. Seizure 13: 241-243.
27. Watemberg N, Goldberg-Stern H, Ben-Zeev B, Berger I, Straussberg R, Kivity S, Kramer U, Brand N, Lerman-Sagie T,. (2003) Clinical experience with open-label topiramate use in infants younger than 2 years of age. J Child Neurol 18: 258-262.